Construction of humanized carcinoembryonic antigen specific single chain variable fragment and mitomycin conjugate

World Journal of Gastroenterology

Volumn 13, Issue 43, 2007, Pages 5765-5770

  Chen, De Jie ^a   Tan, Zui ^a   Chen, Feng ^a   Du, Tian ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Carcinoembryonic antigen; Colorectal cancer; Immunoconjugates; Mitomycin; Single chain variable fragment

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY MITOMYCIN CONJUGATE; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYBRID PROTEIN; RESTRICTION ENDONUCLEASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; COLORECTAL CANCER; CONCENTRATION RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION;

EID: 36248944544     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i43.5765     Document Type: Article

References (30)

1. van Laarhoven HW, Punt CJ. Systemic treatment of advanced colorectal carcinoma. Eur J Gastroenterol Hepatol 2004; 16: 283-289
2. Krol M, Koopman M, Uyl-de Groot C, Punt CJ. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin Pharmacother 2007; 8: 1313-1328
3. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004; 15: 1453-1459
4. Mulders P, Bleumer J, Oosterwijk E. Tumor antigens and markers in renal cell carcinoma. Urol Clin North Am 2003; 30: 455-465
5. Elfiky AA, Saif MW. The developing trend of monoclonal antibodies in the treatment of colorectal cancer. Expert Opin Biol Ther 2007; 7: 871-883
6. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Rearnan GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2006; 24: 190-205
7. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer: Oncogene 2007; 26: 3661-3678
8. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-6837
9. Guillem EB, Sampsel JW. Antitumor-associated antigens IgGs: dual positive and negative potential effects for cancer therapy. Adv Exp Med Biol 2006; 587: 341-374
10. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-356
11. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-462
12. Zimmermann W, Ortlieb B, Friedrich R, von Kleist S. Isolation and characterization of cDNA clones encoding the human carcinoembryonic antigen reveal a highly conserved repeating structure. Proc Natl Acad Sci USA 1987; 84: 2960-2964
13. Shen LZ, Wu WX, Xu DH, Zheng ZC, Liu XY, Ding Q, Hua YB, Yao K. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene. World J Gastroenterol 2002; 8: 270-275
14. O'Dwyer PJ. The present and future of angiogenesis-directed treatments of colorectal cancer. Oncologist 2006; 11: 992-998
15. Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res 1997; 57: 447-453
16. Rodenburg CM, Mernaugh R, Bilbao G, Khazaeli MB. Production of a single chain anti-CEA antibody from the hybridoma cell line T84.66 using a modified colony-lift selection procedure to detect antigen-positive ScFv bacterial clones. Hybridoma 1998; 17: 1-8
17. Gladysheva IF, Polekhina OV, Karmakova TA, Nemtsova ER, Yakubovskaya RI, Shen WC, Kennedy AR, Larionova NI. Potential of block copolymer- and immuno-conjugates for tumor-targeted delivery of Bowman-Birk soybean proteinase inhibitor. J Control Release 2001; 74: 303-308
18. Balch GC, De Meo A, Guillern JG. Modern management of rectal cancer: a 2006 update. World J Gastroenterol 2006; 12: 3186-3195
19. Chung KY, Saltz LB. Antibody-based therapies for colorectal cancer. Oncologist 2005; 10: 701-709
20. Puleo S, Mauro L, Gagliano G, Lombardo R, Li Destri G, Petrillo G, Di Carlo I. Liver damage after transarterial chemoembolization without embolizing agent in unresectable hepatocellular carcinoma. Tumori 2003; 89: 285-287
21. Sharon J, Liebman MA, Williams BR. Recombinant polyclonal antibodies for cancer therapy. J Cell Biochem 2005; 96: 305-313
22. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40: 352-368
23. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002; 13: 603-608
24. Yazaki PJ, Sherman MA, Shively JE, Ikle D, Williams LE, Wong JY, Colcher D, Wu AM, Raubitschek AA. Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Eng Des Sel 2004; 17: 481-489
25. Marinelli A, Vahrmeijer AL, van de Velde Q. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res 1998; 147: 83-94
26. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-129
27. Li Y, Chen Y, Dilley J, Arroyo T, Ko D, Working P, Yu DC. Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol Cancer Ther 2003; 2: 1003-1009
28. Morand EF. New therapeutic target mi inflammatory disease: macrophage udgration. inhibitory factor. Intern Med J 2005; 35: 419-426
29. Park TG, Jeong JH, Kim SW. Current status of polymeric gene delivery systems. Adv Drug Deliv Rev 2006; 58: 467-486
30. Vallejo J, Torres-Avisbal M, Contreras P, Rodriguez-Linan M, Rebollo A, Gonzalez F, Benitez A, Infante J, Mateo A. CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis. Rev Esp Med Nucl 1999; 18: 281-286